Tasquinimod has been shown to inhibit angiogenesis in a variety of models: it inhibits endothelial cell growth and capillary tube formation from aortic rings in in vitro (ex vivo) models, decreases the density of tumour microvessels (CD31-positive) and reduces real-time tumour blood flow and tumour oxygenation in vivo [22]. This evidence concerns the gene PECAM1 and neoplasm.